FarmaMondo Group signs exclusive partnership to commercialize QRX003 for Netherton Syndrome in Singapore

Chiasso, Switzerland and Ashburn, US – 28th July, 2023 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, announces today the signing of a licensing and distribution agreement with Quoin Pharmaceuticals Inc. for exclusive rights to commercialize QRX003 in Singapore.

Advisory Board in Hong Kong

Homozygous Familial Hypercholesterolemia (HoFH) is a rare life-threatening genetic disorder characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C) in the blood and premature